Steven Johnson Syndrome Due to Allopurinol Use

Year 2021, Volume: 3 Issue: 3, 49 - 51, 31.12.2021

Evrim Kar , Abdullah Algın , Hatice Şeyma Akça , Serdar Özdemir , Serkan Emre Eroğlu

https://doi.org/10.51262/ejtox.932679

Abstract

Introduction
Steven Johnson syndrome is a severe cutaneous adverse reaction that develops especially against drugs and has an increasing incidence. The mortality rate in the elderly population is quite high compared to other age groups. Rapid diagnosis, early recognition, and discontinuation of the responsible drug reduce the mortality rate in patients admitted to the emergency department. The most important step in treatment is supportive treatment.
Case
We present a 70-year-old woman with a history of hypertension, coronary artery disease, known renal failure, and adrenal insufficiency. Steven Johnson syndrome developed. We emphasized that the use of allopurinol due to known renal failure and hyperuricemia increased the mortality rate by causing acute kidney damage, and after its rapid diagnosis and treatment, it positively affected mortality. The patient was admitted to the internal medicine service with a pre-diagnosis of Steven Johnson syndrome in the emergency department and was discharged with recommendations after 26 days of hospitalization.
Conclusion
Because of the rapid spread and rapid deterioration of the general condition in severe cutaneous reactions such as Steven Johnson, mortality is important to make a rapid diagnosis, to determine the etiology, and to start treatment early.

Keywords

Steven Johnson Syndrome, Allopurinol, Drug adverse effect

References

• 1. Roujeau JC, Stern RS. Severe Adverse Cutaneous Reactions to Drugs. N Engl J Med. 1994;331(19):1272–85.
• 2. Paulmann M, Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie. JDDG - J Ger Soc Dermatology. 2015;13(7):625–43.
• 3. Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv Ther. 2017;34(6):1235–44.
• 4. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JNB, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.
• 5. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. Scorten: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.
• 6. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–76.
• 7. Harr T, French LE. Stevens-Johnson syndrome and toxic epider- mal necrolysis. Chem Immunol Allergy. 2012 Jan;97:149–66.
• 8. Roujeau JC , Guillaume JC, Fabre JP, Penso D ,Fléchet ML, Girre JP.Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
• 9. Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith M,WangN,Roberts D et al. (2103) Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf36, 953–80
• 10. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7:142-60.
• 11. Kim SC, Newcomb C, Margolis D,RoyJ,Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res. 2013;65(4):578–584.)
• 12.Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case–Control Study. Drug Saf [Internet]. 2019;42(1):55–66. Available from: https://doi.org/10.1007/s40264-018-0711-x
• 13. Saito Y, Stamp LK, Caudle KE, Hershfield MS, McdonaghEM,Callaghan JT. (2016) Clinical Pharmacogenetics Implementation Consortium (CPIC) guide- lines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther 99, 36–7.
• 14. Ghislain PD , Roujeau JC: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hyper- sensitivity syndrome. Dermatol Online J 2002;8:5.)
• 15. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE: Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-53.